A randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients with asymptomatic cerebral oligo-metastases in non-small-cell lung cancer

S. H. Lim, J. Y. Lee, M. Y. Lee, H. S. Kim, J. Lee, J. M. Sun, J. S. Ahn, S. W. Um, H. Kim, B. S. Kim, S. T. Kim, D. L. Na, J. Y. Sun, S. H. Jung, K. Park, O. J. Kwon, J. I. Lee, Myung Ju Ahn

Research output: Contribution to journalArticle

37 Scopus citations

Abstract

Background: It is unclear whether treating brain metastasis before starting systemic chemotherapy can improve survival compared with upfront chemotherapy in non-small-cell lung cancer (NSCLC) with asymptomatic cerebral oligo-metastases. Patients and methods: We undertook a randomized, controlled trial of 105 patients with one to four brain metastases, admitted to Samsung Medical Center between 2008 and 2013. Patients were randomly assigned to receive stereotactic radiosurgery (SRS) (49 patients) followed by chemotherapy or upfront chemotherapy (49 patients). The primary end point was overall survival (OS) and secondary end points included central nervous system (CNS) progression-free survival, progression to symptomatic brain metastasis and brain functional outcome. Results: The median age was 58 years (range, 29-85) with ECOG 0-1 performance status, and 40% of patients were never smokers. Most patients had adenocarcinoma, and about half of patients had only one brain metastasis, while the rest had multiple cerebral metastases. The median OS time was 14.6 months [95% confidence interval (CI), 9.2-20.0] in the SRS group and 15.3 months (95% CI, 7.2-23.4) for the upfront chemotherapy group (P = 0.418). There was no significant difference in time to CNS disease progression [median, 9.4 months (SRS) versus 6.6 months (upfront chemotherapy), P = 0.248]. Symptomatic progression of brain metastases was observed more frequently in the upfront chemotherapy group (26.5%) than the SRS group (18.4%) but without statistical significance. Conclusions: Although this study included smaller sample size than initially anticipated due to early termination, SRS followed by chemotherapy did not improve OS in oligo-brain metastases NSCLC patients compared with upfront chemotherapy. Further study with large number of patients should be needed to confirm the use of upfront chemotherapy alone in this subgroup of patients.

Original languageEnglish
Pages (from-to)762-768
Number of pages7
JournalAnnals of Oncology
Volume26
Issue number4
DOIs
StatePublished - 1 Apr 2015

Keywords

  • Asymptomatic brain metastasis
  • NSCLC
  • Stereotactic radiosurgery (SRS)

Fingerprint Dive into the research topics of 'A randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients with asymptomatic cerebral oligo-metastases in non-small-cell lung cancer'. Together they form a unique fingerprint.

  • Cite this

    Lim, S. H., Lee, J. Y., Lee, M. Y., Kim, H. S., Lee, J., Sun, J. M., Ahn, J. S., Um, S. W., Kim, H., Kim, B. S., Kim, S. T., Na, D. L., Sun, J. Y., Jung, S. H., Park, K., Kwon, O. J., Lee, J. I., & Ahn, M. J. (2015). A randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients with asymptomatic cerebral oligo-metastases in non-small-cell lung cancer. Annals of Oncology, 26(4), 762-768. https://doi.org/10.1093/annonc/mdu584